Heme-bound iron in treatment of pregnancy-associated iron deficiency anemia.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 30613538.
- Also identified by DOI 10.4103/jfmpc.jfmpc_271_18 and PMC identifier 6293905.
- Licence recorded as CC BY-NC-SA.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The iron requirements increase during the second and third trimesters of pregnancy. Maternal anemia is a leading cause of adverse perinatal outcome. This study was designed to evaluate the efficacy of the heme-bound iron in treatment of pregnancy-associated iron deficiency anemia (IDA). In all, 122 women with IDA during pregnancy and hemoglobin ≤10 g/dL were studied. The studied women were treated with heme-bound iron tablets for ≥3 months. Pretreatment hemoglobin, ferritin, mean corpuscular volume (MCV), and mean corpuscular hemoglobin (MCH) were compared with the posttreatment values to detect the efficacy of heme-bound iron (Optifer<sup>®</sup>) in treatment of IDA during pregnancy. The mean pretreatment hemoglobin significantly increased from 8.4 ± 2.7 to 11.2 ± 2.1 g/dL and the mean pretreatment ferritin level significantly increased from 22.6 ± 5.6 to 112.8 ± 4.8 μg/L (<i>P</i> < 0.003 and 0.04; respectively) 3 months after heme-bound iron treatment. In addition, the mean pretreatment red blood cells' MCV and MCH significantly increased from 74.2 ± 4.8 fL and 24.2 ± 7.8 pg, respectively, to 92.0 ± 4.1 fL and 32.6 ± 6.2 pg) (<i>P</i> = 0.04 and 0.007, respectively) 3 months after heme-bound iron treatment. Heme-bound iron (Optifer<sup>®</sup>) is an effective oral iron preparation to treat IDA during pregnancy and to replace the depleted iron store.